By Patrick Wingrove (Reuters) -Swiss drugmaker Novartis said on Monday it has opened a new 10,000-square-foot factory in Carlsbad, California, to make cancer treatments, as part of its pledge to
Novartis Launches New California Facility for Cancer Drug Production
Novartis Expands Manufacturing Capabilities
By Patrick Wingrove
Overview of the New Facility
(Reuters) -Swiss drugmaker Novartis said on Monday it has opened a new 10,000-square-foot factory in Carlsbad, California, to make cancer treatments, as part of its pledge to invest billions into building U.S. sites.
Impact on Cancer Treatment
The plant will produce radioligand therapies, which are drugs that deliver cell-killing radioactive particles directly to tumors, the company said. Novartis already markets radioligand drugs Pluvicto for prostate cancer and Lutathera for rare gastrointestinal tumors.
Company's Investment Strategy
The new factory will speed up and stabilize delivery of radioligand therapy doses to patients across the western U.S., Alaska, and Hawaii, Novartis said.
Novartis in April pledged $23 billion to build and expand 10 facilities in the U.S., as it grappled with renewed threats of drug import duties from the Trump administration.
The company said it planned to build six new manufacturing plants, some of which will make raw pharmaceutical ingredients, as well as a new research and development site in San Diego, California.
(Reporting by Patrick Wingrove in New York; Editing by Bill Berkrot)
